Atlas Venture Fund XI, L.P. 13D and 13G filings for Dyne Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:32 pm Sale |
2024-09-30 | 13G | Dyne Therapeutics, Inc. DYN |
Atlas Venture Fund XI, L.P. | 5,714,057 5.700% |
-1,628,026 (-22.17%) |
Filing |
| 2024-02-09 4:09 pm Purchase |
2023-12-31 | 13G | Dyne Therapeutics, Inc. DYN |
Atlas Venture Fund XI, L.P. | 7,342,083 9.100% |
15,966 (+0.22%) |
Filing |
| 2023-02-14 4:29 pm Unchanged |
2022-12-31 | 13G | Dyne Therapeutics, Inc. DYN |
Atlas Venture Fund XI, L.P. | 7,326,117 14.100% |
0 (Unchanged) |
Filing |
| 2022-02-11 5:04 pm Sale |
2021-12-31 | 13G | Dyne Therapeutics, Inc. DYN |
Atlas Venture Fund XI, L.P. | 7,326,117 14.200% |
-814,013 (-10.00%) |
Filing |
| 2021-02-16 5:28 pm Purchase |
2020-12-31 | 13G | Dyne Therapeutics, Inc. DYN |
Atlas Venture Fund XI, L.P. | 8,140,130 17.900% |
8,140,130 (New Position) |
Filing |